Eleven Biotherapeutics Inc. (NASDAQ:EBIO) major shareholder Ventures Fund Iv L.P Flagship sold 9,700 shares of the company’s stock in a transaction dated Monday, September 19th. The shares were sold at an average price of $3.31, for a total transaction of $32,107.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Ventures Fund Iv L.P Flagship also recently made the following trade(s):

  • On Wednesday, September 21st, Ventures Fund Iv L.P Flagship sold 322,723 shares of Eleven Biotherapeutics stock. The shares were sold at an average price of $3.75, for a total transaction of $1,210,211.25.
  • On Tuesday, September 20th, Ventures Fund Iv L.P Flagship sold 53,917 shares of Eleven Biotherapeutics stock. The shares were sold at an average price of $3.39, for a total transaction of $182,778.63.

Eleven Biotherapeutics Inc. (NASDAQ:EBIO) traded up 3.86% on Wednesday, hitting $3.50. 6,214,655 shares of the stock were exchanged. The company’s market cap is $53.88 million. The company’s 50-day moving average is $4.45 and its 200-day moving average is $2.19. Eleven Biotherapeutics Inc. has a 52 week low of $0.25 and a 52 week high of $5.97.

Eleven Biotherapeutics (NASDAQ:EBIO) last issued its quarterly earnings data on Friday, August 12th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter. Eleven Biotherapeutics had a negative net margin of 2,995.34% and a negative return on equity of 207.40%. On average, analysts predict that Eleven Biotherapeutics Inc. will post ($1.75) earnings per share for the current year.

A number of institutional investors have recently modified their holdings of the stock. Bank of New York Mellon Corp increased its position in shares of Eleven Biotherapeutics by 13.2% in the second quarter. Bank of New York Mellon Corp now owns 67,483 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 7,846 shares during the last quarter. Sabby Management LLC increased its position in shares of Eleven Biotherapeutics by 525.6% in the first quarter. Sabby Management LLC now owns 1,213,984 shares of the biopharmaceutical company’s stock valued at $387,000 after buying an additional 1,019,943 shares during the last quarter. Flagship Ventures Fund IV L.P. acquired a new position in shares of Eleven Biotherapeutics during the first quarter valued at about $469,000. Flagship Ventures Fund 2007 L.P. acquired a new position in shares of Eleven Biotherapeutics during the first quarter valued at about $610,000. Finally, Boxer Capital LLC acquired a new position in shares of Eleven Biotherapeutics during the second quarter valued at about $1,670,000. Hedge funds and other institutional investors own 24.81% of the company’s stock.

Eleven Biotherapeutics Company Profile

Eleven Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company through AMP-Rx, a protein engineering platform, is engaged in the discovery and development of protein therapeutics to treat diseases of the eye. The Company designs, engineers and generates a pipeline of protein therapeutic candidates that target cytokines, which are central to diseases of the eye.

5 Day Chart for NASDAQ:EBIO

Receive News & Ratings for Eleven Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eleven Biotherapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.